Durham biopharma makes big pivot with $300M deal for gene therapy drug
Published . Updated .
This report is about pharma and health.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
- MRK Merck+3.2% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -3.03% | -2.77% | base | after close | after close | after close | after close |
| XBI | -3.49% | +0.99% | base | after close | after close | after close | after close |
| LLY | -9.71% | -8.92% | base | after close | after close | after close | after close |
| JNJ | -2.53% | -0.72% | base | after close | after close | after close | after close |
| PFE | -2.33% | -3.34% | base | after close | after close | after close | after close |
| MRK | -5.94% | -5.65% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Durham biopharma makes big pivot with $300M deal for gene therapy drug The Business Journals
Source: The Business Journals
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | -0.72% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -2.53% | final price |
| Eli Lilly (LLY) | three days earlier | -8.92% | final price |
| Eli Lilly (LLY) | five days earlier | -9.71% | final price |
| Merck (MRK) | three days earlier | -5.65% | final price |
| Merck (MRK) | five days earlier | -5.94% | final price |
| Pfizer (PFE) | three days earlier | -3.34% | final price |
| Pfizer (PFE) | five days earlier | -2.33% | final price |
| Spdr Series Trust (XBI) | three days earlier | +0.99% | final price |
| Spdr Series Trust (XBI) | five days earlier | -3.49% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -2.77% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -3.03% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 37 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 54 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 58 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 72 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 74 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies carried with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 1 Nov 2026 story “Durham biopharma makes big pivot with $300M deal for gene therapy drug.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
- XBI Spdr Series Trust
For “Durham biopharma makes big pivot with $300M deal for gene therapy drug,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
- LLY Eli Lilly
In “Durham biopharma makes big pivot with $300M deal for gene therapy drug,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Durham biopharma makes big pivot with $300M deal for gene therapy drug,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- PFE Pfizer
In “Durham biopharma makes big pivot with $300M deal for gene therapy drug,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
- MRK Merck
For “Durham biopharma makes big pivot with $300M deal for gene therapy drug,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “drug” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
“Durham biopharma makes big pivot with $300M deal for gene therapy drug” (1 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “drug” (pharma and health) in this story
The price range for Select Sector Spdr Tr (XLV), and the dates in the story
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1415.62.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Durham biopharma makes big pivot with $300M deal for gene therapy drug” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.